[PDF][PDF] Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells

T Muranen, LM Selfors, DT Worster, MP Iwanicki… - Cancer cell, 2012 - cell.com
T Muranen, LM Selfors, DT Worster, MP Iwanicki, L Song, FC Morales, S Gao, GB Mills
Cancer cell, 2012cell.com
Summary The PI3K/mTOR-pathway is the most commonly dysregulated pathway in
epithelial cancers and represents an important target for cancer therapeutics. Here, we show
that dual inhibition of PI3K/mTOR in ovarian cancer-spheroids leads to death of inner matrix-
deprived cells, whereas matrix-attached cells are resistant. This matrix-associated
resistance is mediated by drug-induced upregulation of cellular survival programs that
involve both FOXO-regulated transcription and cap-independent translation. Inhibition of any …
Summary
The PI3K/mTOR-pathway is the most commonly dysregulated pathway in epithelial cancers and represents an important target for cancer therapeutics. Here, we show that dual inhibition of PI3K/mTOR in ovarian cancer-spheroids leads to death of inner matrix-deprived cells, whereas matrix-attached cells are resistant. This matrix-associated resistance is mediated by drug-induced upregulation of cellular survival programs that involve both FOXO-regulated transcription and cap-independent translation. Inhibition of any one of several upregulated proteins, including Bcl-2, EGFR, or IGF1R, abrogates resistance to PI3K/mTOR inhibition. These results demonstrate that acute adaptive responses to PI3K/mTOR inhibition in matrix-attached cells resemble well-conserved stress responses to nutrient and growth factor deprivation. Bypass of this resistance mechanism through rational design of drug combinations could significantly enhance PI3K-targeted drug efficacy.
cell.com